Peak Bio Inc. (PKBO)
0.02
null (null%)
At close: Nov 14, 2024, 8:00 PM
Company Description
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation.
The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients.
Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD).
The company is based in Palo Alto, California.
Peak Bio Inc.
| Country | United States |
| IPO Date | Mar 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Dr. Hoyoung Huh M.D., Ph.D. |
Contact Details
Address: 3350 W Bayshore Rd. Palo Alto, California United States | |
| Website | https://peak-bio.com |
Stock Details
| Ticker Symbol | PKBO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001834645 |
| CUSIP Number | 70470P108 |
| ISIN Number | US70470P1084 |
| Employer ID | 85-2448157 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Divya Patel CPA | Acting Chief Financial Officer |
| Dr. Hoyoung Huh M.D., Ph.D. | Executive Chairman |
| Dr. Satyajit Mitra Ph.D. | Head of Oncology & Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Dec 04, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 15, 2024 | 15-12G | Filing |
| Nov 14, 2024 | POS AM | Filing |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |